Vanguard Australian Shares High Yield Etf

VHY

VHY.AX was created on 2011-05-26 by Vanguard. The fund's investment portfolio concentrates primarily on high dividend yield equity. Vanguard Australian Shares High Yield ETF seeks to track the return of the FTSE Australia High Dividend Yield Index before taking into account fees, expenses and tax.

Actinogen Medical Limited

ACW

Actinogen Medical Ltd. is a clinical stage Australian biotechnology company, which focuses on the development of novel treatments or cognitive impairment associated with neurological, psychiatric, and metabolic diseases due to raised cortisol. The company is headquartered in Sydney, New South Wales. The company went IPO on 2007-10-16. The firm is engaged in the development of a therapy for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol. The company is engaged in the development of its lead compound, Xanamem, as a therapy for Alzheimer’s Disease, Major Depressive Disorder, Fragile X Syndrome, and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. Xanamem’s mechanism of action is to block the production of cortisol inside cells through the inhibition of the 11B-HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule. The company has studied 11B-HSD1 inhibition by Xanamem in approximately 300 volunteers and patients. The firm conducts a series of Phase II studies in multiple diseases to further confirm and characterize Xanamem’s therapeutic potential.

Aft Pharmaceuticals Limited

AFP

AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories around the world. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's product portfolio targets various therapeutic areas, such as pain, eyecare, vitamins, allergy, gastrointestinal, dermatology and hospital. Its products include Maxigesic, ParaOsteo, ZoRub OA/HP, Fenpaed, Combolieve Day/Night, Hylo, Novatears, CromoFresh, Opti-soothe Wipes/Mask, VitAPOS, Ferro-liquid, FerroTab, Ferro-F, Ferro-sachets, Lipo VitC, Lipo VitD, CalciTab, Loraclear, Histaclear, Fexaclear, Levoclear, Allersoothe, Lorapaed, Becloclear, Steroclear, Gastrosoothe/Forte, LaxTab, Micolette, Nausicalm, DiaRelieve, Crystaderm, Crystawash Hand Sanitizer, Crystasoothe, ZoRub anti-chafing, Decazol, MycoNail and others.

Althea Group Holdings Limited

AGH

Althea Group Holdings Ltd. is an investment company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2018-09-21. The firm services these sectors via two business units: Althea and Peak Processing Solutions. Althea is its pharmaceutical business that offers a range of cannabis-based medicines which are made available to patients via prescription. Althea offers a range of education, access, and management services to support eligible patients and healthcare professionals in navigating medicinal cannabis treatment pathways. Peak Processing Solutions is its recreational cannabis business, which produces legal cannabis products purchased by adult consumers in retail stores. Peak Processing Solutions provides formulation and mass-manufacturing of recreational cannabis products, including beverages, concentrates, topicals and others. The firm operates in regulated and legal cannabis markets across Europe, North America, Australia, and Africa.

A200

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 2975.21m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.